A股異動丨再籤超預期大單 凱萊英(002821.SZ)創歷史新高
格隆匯11月29日丨凱萊英(002821.SZ)大幅收漲9.82%,盤中高見525.58元再度刷新歷史高價,月內更是升幅達32%,總市值1284.2億元。公司近日再次與客户簽訂了相關產品新一批的《供貨合同》,本次合同金額摺合人民幣約27.20億元。疊加11月16日公司公吿簽署4.81億美金重大合同,意味着2022年公司收入端有可能在此次超預期。浙商證券認為公司持續獲得超預期大訂單是對公司能力的進一步驗證,也為後續獲得更多優質訂單打下基礎,看好公司產業鏈地位持續提升趨勢。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.